Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Free Cash Flow (2023 - 2025)

Metagenomi (MGX) has disclosed Free Cash Flow for 3 consecutive years, with -$24.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 9.63% to -$24.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$89.5 million, a 20.25% increase, with the full-year FY2025 number at -$89.5 million, up 20.25% from a year prior.
  • Free Cash Flow was -$24.0 million for Q4 2025 at Metagenomi, down from -$21.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$21.0 million in Q2 2025 to a low of -$30.8 million in Q1 2024.
  • A 3-year average of -$25.2 million and a median of -$25.0 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 30.01% in 2024, then grew 24.82% in 2025.
  • Metagenomi's Free Cash Flow stood at -$22.3 million in 2023, then fell by 19.17% to -$26.6 million in 2024, then rose by 9.63% to -$24.0 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Free Cash Flow are -$24.0 million (Q4 2025), -$21.3 million (Q3 2025), and -$21.0 million (Q2 2025).